Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | GLP1R | P43220 | 1/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 1.00 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 1.00 |
| ▸ | CCR3 | P51677 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885401 | 1.00 | CCR2 (1.00) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL14896310 | 1.00 | CCR2 (1.00) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL3885399 | 1.00 | CCR2 (1.00) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL3897177 | 0.92 | CCR2 (0.85) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL3888817 | 0.92 | CCR2 (0.85) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL3888816 | 0.92 | CCR2 (0.85) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL5947568 | 0.91 | CCR2 (0.84) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL3892399 | 0.91 | CCR2 (0.84) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL3892402 | 0.91 | CCR2 (0.84) | CCR2ADRB2HRH1DRD3GLP1R | |
| SCHEMBL3899694 | 0.91 | CCR2 (0.83) | CCR2ADRB2HRH1DRD3GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197637-A1 | POLYMERIC MICROPARTICLES FOR THE LOCAL TREATMENT OF CHRONIC INFLAMMATORY DISEASES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-20 | — | — | US | claimed |
| EP-4322923-A1 | POLYMERIC MICROPARTICLES FOR THE LOCAL TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Fondazione Istituto Italiano di Tecnologia (IT) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219089-A1 | POLYMERIC MICROPARTICLES FOR THE LOCAL TREATMENT OF CHRONIC INFLAMMATORY DISEASES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2022-10-20 | — | — | WO | claimed |
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | TRANSLATUM MEDICUS INC (CA) | 2026-01-08 | — | — | US | disclosed |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | OHIO STATE INNOVATION FOUNDATION (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2024178368-A2 | THERAPEUTIC PROTEIN COMBINATIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240197637-A1 | POLYMERIC MICROPARTICLES FOR THE LOCAL TREATMENT OF CHRONIC INFLAMMATORY DISEASES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-20 | — | — | US | disclosed |
| US-20230398063-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | OHIO STATE INNOVATION FOUNDATION | 2023-12-14 | — | — | US | disclosed |
| WO-2023133560-A2 | TISSUE ENGINEERING AND DRUG DELIVERY DEVICE | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2022271255-A1 | TISSUE-ENGINEERED SCAFFOLDS AND METHODS OF MAKING | GEORGIA TECH RESEARCH CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | AGER, ALDH1A2, RBP1 | CCR2 1297/4885ADRB2 501/4885HRH1 173/4885 |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | PDE6C, CHMP4B, PDE6D | CCR2 4347/4885ADRB2 1717/4885HRH1 3888/4885 |
| US-20230398063-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | PDE6C, CHMP4B, PDE6D | CCR2 4347/4885ADRB2 1717/4885HRH1 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.